Clinical trials: Renal Failure Chronic
Chronic Kidney Disease
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
- Trial name
- NCT00985426
- Testing
- HEPLISAV-B, Engerix-B
- Where
- United States
- Volunteers
- 521 people
- Sponsor
- Dynavax Technologies Corporation
Chronic Kidney Disease
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
1) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite…
- Trial name
- NCT00500682
- Testing
- AST-120
- Where
- 105 sites in United States, Argentina and 10 more
- Volunteers
- 1,020 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Diseases, Renal Anemia
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
To evaluate the safety, tolerability , pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Patients With Non-dialysis Renal Anemia.
- Trial name
- NCT04925661
- Testing
- HEC53856, Roxadustat
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Kidney Disease, Hypertension
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
- Trial name
- NCT05491642
- Testing
- BAY3283142
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 56 people
- Sponsor
- Bayer
Chronic Hepatitis C, Hepatitis C Virus
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24-week regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis, Severe Renal Impairment
- Trial name
- NCT02207088
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, Ribavirin
- Volunteers
- 68 people
- Sponsor
- AbbVie
Anemia
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
This single arm study will assess the efficacy, safety and tolerability of monthly intravenous Mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal disease, currently receiving epoetin alfa or…
- Trial name
- NCT00576303
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 18 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
- Trial name
- NCT02062203
- Testing
- AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
End Stage Renal Disease
Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients
The FAST Plasma Volume (PV) Technology will aid in determining the plasma and interstitial volumes of end stage renal disease patients before and after dialysis therapy, providing a more precise understanding of pre and post…
- Trial name
- NCT04733664
- Testing
- VFI using the FAST PV Technology
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- FAST BioMedical
Anaemia
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
This study will be conducted in approximately 228 subjects with anemia associated with CKD who are not on dialysis. Two groups of subjects will be enrolled into the study: Group 1: recombinant human erythropoietin (rhEPO) naive…
- Trial name
- NCT01977573
- Testing
- GSK1278863, rhEPO
- Where
- 123 sites in United States, Australia and 13 more
- Volunteers
- 252 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad…
- Conditions
- Chronic Kidney Disease, Inflammation, Cardiovascular Risk
- Trial name
- RESCUE-2 (NCT04626505)
- Testing
- Ziltivekimab
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI HD-C (NCT03351166)
- Testing
- Molidustat (BAY85-3934)
- Where
- 20 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Bayer
Vascular Diseases, End Stage Renal Disease on Dialysis
Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access
Individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study.
- Trial name
- NCT07141641
- Testing
- Acellular Tissue Engineered Vessel (ATEV)
- Sponsor
- Humacyte, Inc.
End-Stage Renal Disease, End-Stage Kidney Disease
A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
This was intended as a three-part study of MK-2060 in participants with chronic and/or end-stage kidney disease (Parts 2 and 3 were not initiated due to reasons not related to safety).
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05656040
- Testing
- MK-2060
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease, Arterial Hypertension
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure.
- Trial name
- NCT06428825
- Testing
- BAY3283142
- Where
- 2 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Kidney Failure, Chronic, Renal Disease, End-Stage
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients.
- Trial name
- NCT00035178
- Testing
- Argatroban
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Texas Biotechnology Corporation
Chronic Kidney Diseases
Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure
The main objective of this study is to demonstrate the efficiency ( cost-effectiveness ) of a telemedicine system : eNephro Application , compared with traditional care in the management of chronic renal failure in different…
- Trial name
- eNephro (NCT02082093)
- Testing
- Telemedicine System
- Where
- 8 sites in France
- Volunteers
- 635 people
- Sponsor
- Pharmagest Interactive
End Stage Renal Disease (ESRD)
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage…
- Trial name
- NCT05908084
- Testing
- Acellular Tissue Engineered Vessel (ATEV), AVF
- Where
- 32 sites in United States
- Volunteers
- 121 people
- Sponsor
- Humacyte, Inc.
End Stage Renal Disease
Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis
The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence of intradialytic morbid events in dialysis…
- Trial name
- SODIAH (NCT06341452)
- Testing
- Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
- Where
- Czechia
- Volunteers
- 130 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.